Funding for this research was provided by:
Foundation for Influenza Epidemiology (GIHSN grant 2017/18)
National Institute for Infectious Diseases ‘Prof. Dr. Matei Balş’, Bucharest, Romania
Received: 14 May 2019
Accepted: 31 October 2019
First Online: 12 November 2019
Ethics approval and consent to participate
: The study was approved by the Bioethics Committee of the National Institute for Infectious Diseases ‘Prof. Dr. Matei Balș’ and was conducted in accordance with Good Clinical Practice. All patients, their parents or legal guardians, or their next of kin provided their written informed consent.
: Not applicable.
: AD, OS, DF, OV, DO, Anca SC, MLL, VA, Adrian SC and DP work within the GIHSN project funded by the National Institute for Infectious Diseases 'Prof. Dr. Matei Balș', Bucharest, Romania, and the Foundation for Influenza Epidemiology, and within the DRIVE study supported by the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant n° 777363).Anca SC and DP have been investigators in the I-MOVE+ study funded through the European Union’s HORIZON 2020 research and innovation.OS, Anca SC, and Adrian SC have been investigators in influenza clinical trials by Shionogi and F. Hoffmann-La Roche.SA is an employee of Sanofi Pasteur.